JP
Revvity Sites Globally
Select your location.
*e-commerce not available for this region.
Literature - Publication Review
Advancing α-Synuclein pathology insights for targeted Parkinson’s disease therapies
This publication review is based on recent research focused on characterizing α -synuclein pathology in preclinical models, employing AlphaLISA™ SureFire® Ultra assays to measure total and phosphorylated S129 α-synuclein levels, along with the BioLegend LEGEND MAX™ α-Synuclein Aggregate ELISA assay.
This publication review details:
- Detection of α-synuclein and pS129 in mouse and human samples
- Validated performance across tissues and cell models with minimal background
- Link between phosphorylation and aggregation in diseased brain regions
- Scalable platform for biomarker discovery and therapeutic research in synucleinopathies
For research use only. Not for use in diagnostic procedures.
To view the full content please answer a few questions
Download Resource
Advancing α-Synuclein pathology insights for targeted Parkinson’s disease therapies